Objectives: Recalcitrant macular disorders are those retinal conditions which, though treated by various medical and surgical modalities, but showedno improvement in symptoms or visual acuity or both. The present study was carried out to evaluate the efficacy of intravitreal triamcinoloneacetonide (TA) injection in patients with these recalcitrant macular disorders.Methods: This prospective and interventional study included 40 patients (40 eyes) having recalcitrant macular disorders. Complete ophthalmicexamination such as measurement of intraocular pressure (IOP), visual acuity (log minimal angle of resolution [MAR] units), fundus photography withfluorescein angiography were carried out before and after intravitreal injection of TA. The patients received an intravitreal injection of TA (10 mg) fordiabetic macular edema (n=14), age-related macular degeneration (n=13), pars plana cystoid macular edema (CME) (n=5), vascular diseases (n=3),central chorioretinopathy (n=3), and idiopathic CME (n=2). The follow-up was done on day 1, day 7, 1 month, 2 month and 4-month intervals.Results: The mean visual acuity at 2 months (1.12±0.45 log MAR units), and 4 months (1.08±0.46 log MAR unit) after the injection were significantlybetter than baseline measurements (1.32±0.3 log MAR units). The mean baseline IOP was 12.5±2.9 mmHg. The IOP significantly increased after theinjection at day 1 and day 7; however, the change in IOP at 1 month, 2 months, and 4 months was not statistically significant.Conclusion: The results indicate that intravitreal injection of TA in patients with recalcitrant macular disorders caused significant improvement ofvisual acuity in 10 mg dose.Keywords: Intravitreal triamcinolone acetonide, Macular edema, Visual acuity, Intraocular pressure
